Vor Bio announced initial clinical data from VBP101, its Phase 1/2a multicenter, open-label, first- in-human study of tremtelectogene empogeditemcel or "trem-cel" (formerly VOR33) in patients with acute myeloid leukemia (AML). The data observed from the first treated patient support the potential of a trem-cel transplant to be successfully manufactured, to engraft normally, and to maintain blood counts following treatment with the CD33-targeted therapy Mylotarg. The clinical trial continues to enroll patients and additional data are expected in 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1 USD | -12.28% | -15.97% | -55.56% |
13/06 | Voyager Therapeutics Names Nathan Jorgensen as Finance Chief | MT |
10/06 | Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-55.56% | 68.26M | |
+19.41% | 45.51B | |
+38.65% | 38.13B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- VOR Stock
- News Vor Biopharma Inc.
- Vor Bio Announces First AML Patient Successfully Transplanted with VOR Bio's Investigational Trem-Cel and Tolerated Mylotarg(Tm)